RÃ©gis T Costello

List of Publications by Year
in descending order

91 papers	3,037 citations	172457 29 h-index	168389 53 g-index
102 all docs	102 docs citations	102 times ranked	3819 citing authors

#	Article	IF	Citations
1	Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?â€"Potential therapeutic applications. European Journal of Haematology, 2021, 106, 589-592.	2.2	3
2	Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e503-e505.	0.4	3
3	The contribution of single-cell analysis of acute leukemia in the therapeutic strategy. Biomarker Research, 2021, 9, 50.	6.8	9
4	Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue. Annals of Hematology, 2021, 100, 2799-2803.	1.8	14
5	In situ BCL2 expression is an independent prognostic factor in HIVâ€associated DLBCL, a LYMPHOVIR cohort study. British Journal of Haematology, 2020, 188, 413-423.	2.5	5
6	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. Aids, 2020, 34, 599-608.	2.2	7
7	High Serum Vitamin B12 Levels Associated with Câ€Reactive Protein in Older Patients with Cancer. Oncologist, 2020, 25, e1980-e1989.	3.7	5
8	Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. European Journal of Internal Medicine, 2019, 68, 71-75.	2.2	16
9	A transcriptomic signature predicting septic outcome in patients undergoing autologous stem cell transplantation. Experimental Hematology, 2018, 65, 49-56.	0.4	5
10	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. Aids, 2017, 31, 2493-2501.	2.2	51
11	Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of SÃ©zary T lymphoma: a transcriptomic approach. Archives of Dermatological Research, 2017, 309, 611-623.	1.9	6
12	Is R-CHOP Therapy a Lymphoma Growth Factor?. American Journal of Therapeutics, 2016, 23, e295-e297.	0.9	1
13	Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 431-441.	4.5	54
14	Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts. Leukemia Research Reports, 2015, 4, 15-17.	0.4	1
15	Distribution of lymphocyte subpopulations in patients with polycythemia vera. Human Immunology, 2015, 76, 414-416.	2.4	4
16	Natural killer cells in patients with polycythemia vera. Human Immunology, 2015, 76, 644-650.	2.4	3
17	Recurrent hepatic hematoma due to familial lysozyme amyloidosis resolves with conservative management. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 66-68.	3.0	3
18	Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients. AIDS Research and Therapy, 2014, 11, 38.	1.7	5

#	Article	IF	Citations
19	Pulmonary hypertension in patients with chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2014, 55, 223-225.	1.3	18
20	Natural Killer Cells Modulation in Hematological Malignancies. Frontiers in Immunology, 2013, 4, 459.	4.8	29
21	Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology, 2013, 139, 338-341.	4.4	54
22	Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients During the Combined Antiretroviral Therapy Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 249-253.	2.1	12
23	MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thrombosis and Haemostasis, 2013, 110, 844-851.	3.4	52
24	Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	52
25	Recurrent superior vena cava syndrome caused by IgD multiple myeloma. Annals of Hematology, 2012, 91, 1977-1978.	1.8	1
26	Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. Immunology, 2012, 135, 151-157.	4.4	44
27	Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunology, Immunotherapy, 2011, 60, 1-13.	4.2	38
28	Bone marrow necrosis and sickle cell crisis associated with double heterozygosity for HbS and HbOARAB. American Journal of Hematology, 2011, 86, 309-310.	4.1	8
29	Agranulocytosis occurring in a patient with chronic lymphocytic leukemia in complete remission; treatment by rituximab and cyclosporin. Leukemia Research, 2010, 34, e329-e330.	0.8	3
30	Chronic eosinophilic leukaemia revealed by lymphomatoid papulosis: the role of the FIP1â€likeÂ1â€plateletâ€derived growth factor receptor alpha fusion gene. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 234-234.	2.4	10
31	Natural killer cells in leukaemia. , 2010, , 533-541.		0
32	Peripheral Tâ€cell lymphoma gene expression profiling and potential therapeutic exploitations. British Journal of Haematology, 2010, 150, 21-27.	2.5	17
33	A role for HVEM, but not lymphotoxinâ€Î² receptor, in LIGHTâ€induced tumor cell death and chemokine production. European Journal of Immunology, 2009, 39, 2502-2514.	2.9	33
34	How to restore normal innate antitumor immunity in acute leukemia?. Leukemia Research, 2009, 33, 613.	0.8	2
35	Reversing the multidrug resistance in acute leukemia: Until the leukemia initiating cell?. Leukemia Research, 2009, 33, 749.	0.8	0
36	Good outcome after rituximab treatment for a mixed warm and cold autoimmune haemolytic anaemia. BMJ Case Reports, 2009, 2009, bcr0920080857-bcr0920080857.	0.5	1

#	Article	IF	Citations
37	Rank ligand stimulation induces a partial but functional maturation of human monocyte-derived dendritic cells. European Cytokine Network, 2008, 19, 81-8.	2.0	7
38	Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood, 2007, 109, 323-330.	1.4	321
39	Gaucher disease and multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1365-1368.	1.3	35
40	Non-Hodgkin's lymphoma after kidney transplantation: A single institution study. Leukemia Research, 2006, 30, 118-119.	0.8	1
41	The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function. European Journal of Immunology, 2006, 36, 2359-2366.	2.9	55
42	Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. Blood, 2005, 106, 2186-2188.	1.4	60
43	LIGHT costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T cell-dependent B cell terminal differentiation. European Journal of Immunology, 2004, 34, 3534-3541.	2.9	56
44	Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus. Cancer, 2004, 100, 667-676.	4.1	15
45	NK cells: innate immunity against hematological malignancies?. Trends in Immunology, 2004, 25, 328-333.	6.8	65
46	Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols. Lancet Oncology, The, 2004, 5, 47-55.	10.7	10
47	Natural killer cells and immunity against cancer. Discovery Medicine, 2004, 4, 333-7.	0.5	1
48	New approaches in the immunotherapy of haematological malignancies. European Journal of Haematology, 2003, 70, 333-345.	2.2	23
49	Granular lymphoproliferative disorder, autologous blood stem cell transplantation and multiple myeloma. European Journal of Haematology, 2003, 71, 311-312.	2.2	0
50	LIGHT, a new TNF superfamily member, is essential for memory T helper cell-mediated activation of dendritic cells. European Journal of Immunology, 2003, 33, 3213-3219.	2.9	21
51	Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia, 2003, 17, 2500-2507.	7.2	40
52	Natural Killer Cell-triggering Receptors in Patients with Acute Leukaemia. Leukemia and Lymphoma, 2003, 44, 1683-1689.	1.3	17
53	Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma. Aids, 2003, 17, 2006-2007.	2.2	5
54	Mechanisms Regulating Expression of the Tumor Necrosis Factor-related light Gene. Journal of Biological Chemistry, 2002, 277, 42841-42851.	3.4	20

#	Article	IF	Citations
55	A novel mechanism of antitumor response involving the expansion of CD3+/CD56+ large granular lymphocytes triggered by a tumor-expressed activating ligand. Leukemia, 2002, 16, 855-860.	7.2	19
56	Defective expression and function of natural killer cellâ€“triggering receptors in patients with acute myeloid leukemia. Blood, 2002, 99, 3661-3667.	1.4	434
57	Three-year outcome in a patient with Staphylococcus lugdunensis discitis. Joint Bone Spine, 2002, 69, 85-87.	1.6	12
58	Immune reconstitution during intensive chemotherapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma. The Hematology Journal, 2002, 3, 216-218.	1.4	3
59	Human immunodeficiency virusâ€“related lymphoma: relation between clinical features and histologic subtypes. American Journal of Medicine, 2001, 111, 704-711.	1.5	62
60	Primary plasma cell leukaemia: a report of 18 cases. Leukemia Research, 2001, 25, 103-107.	0.8	78
61	The TNF Superfamily Members LIGHT and CD154 (CD40 Ligand) Costimulate Induction of Dendritic Cell Maturation and Elicit Specific CTL Activity. Journal of Immunology, 2001, 167, 2479-2486.	0.8	163
62	Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: Engagement of CD33 induces apoptosis of leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5764-5769.	7.1	100
63	Acute myeloid leukaemia triggering via CD40 induces leukocyte chemoattraction and cytotoxicity against allogenic or autologous leukemic targets. Leukemia, 2000, 14, 123-128.	7.2	13
64	Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center. Bone Marrow Transplantation, 2000, 25, 35-40.	2.4	12
65	Reciprocal Expression of the TNF Family Receptor Herpes Virus Entry Mediator and Its Ligand LIGHT on Activated T Cells: LIGHT Down-Regulates Its Own Receptor. Journal of Immunology, 2000, 165, 4397-4404.	0.8	161
66	Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy. Annals of Oncology, 1999, 10, 362-363.	1.2	20
67	What is the real role of CD40 in cancer immunotherapy?. Trends in Immunology, 1999, 20, 488-493.	7.5	75
68	The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38â^' leukemic progenitors. Leukemia, 1999, 13, 1513-1518.	7.2	41
69	First case of plasma-cell leukemia co-existing with human immunodeficiency virus infection. Leukemia, 1998, 12, 103-104.	7.2	6
70	Rapid evolution of multiple myeloma after cobalamin therapy for megaloblastic erythropoiesis with macrocytic anemia. Leukemia Research, 1998, 22, 287.	0.8	6
71	Askin Tumor and Acute Myeloid Leukemia in a Patient with Constitutional Partial Y Disomy. Cancer Genetics and Cytogenetics, 1998, 103, 11-14.	1.0	4
72	Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. European Journal of Immunology, 1998, 28, 90-103.	2.9	78

#	Article	IF	Citations
73	The Philadelphia chromosome as a secondary abnormality in two cases of acute myeloid leukemia. British Journal of Haematology, 1998, 102, 873-875.	2.5	17
74	Clinical and biological aspects of philadelphia-Negative/BCR-Negative chronic myeloid leukemia. Leukemia and Lymphoma, 1997, 25, 225-232.	1.3	28
75	Detection of CBFÎ²/MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics. Leukemia, 1997, 11, 644-650.	7.2	38
76	Identification of a myeloma variant with aggressive biological and clinical characteristics: â€œEarlyâ€• plasma cell meningitis. , 1997, 56, 295-296.		3
77	Leukopenia, thrombocytopenia, and acute autoimmune hemolytic anemia associated with an unusual (type 2/4) Hodgkin's disease: Case report. , 1996, 52, 333-334.		6
78	Pseudo-â€œacid retinoic syndromeâ€•mimicked by severe influenza A infection. American Journal of Hematology, 1996, 52, 120-120.	4.1	1
79	Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leukemia and Lymphoma, 1996, 20, 239-243.	1.3	25
80	Philadelphia chromosomeâ€•negative chronic myeloid leukaemia: a report of 14 new cases. British Journal of Haematology, 1995, 90, 346-352.	2.5	30
81	Minor breakpoint cluster region (m-BCR) positive chronic myeloid leukaemia with an acute lymphoblastic leukaemia onset: a case report. British Journal of Haematology, 1995, 91, 428-430.	2.5	15
82	Third case of acute monocytic leukemia (M5) occurring in an HIV-Seropositive man: A case report. American Journal of Hematology, 1995, 49, 356-357.	4.1	11
83	Unbalanced translocation t(5;17) in an atypical acute promyelocytic leukemia. Genes Chromosomes and Cancer, 1995, 14, 307-312.	2.8	22
84	Translocation of BCR to chromosome 9 in a Philadelphia-negative chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 1995, 85, 82-84.	1.0	25
85	The CD2 and CD28 adhesion molecules induce long-term autocrine proliferation of CD4+ T cells. European Journal of Immunology, 1993, 23, 608-613.	2.9	43
86	Therapeutic Use of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): A review of recent experience. Acta OncolÃ³gica, 1993, 32, 403-408.	1.8	19
87	Pretransplantation Blood Transfusion. New England Journal of Medicine, 1992, 326, 1027-1028.	27.0	0
88	Maladie de Horton et leucÃ©mie lymphoÃ¯de chronique. Revue De Medecine Interne, 1992, 13, 472.	1.0	2
89	Macrophage colony-stimulating factor production in leukemic cell lines compared to normal T cells. Leukemia Research, 1992, 16, 723.	0.8	1
90	INTERLEUKIN 2 AND ITS PLEIOTROPIC EFFECTS. British Journal of Haematology, 1991, 79, 345-345.	2.5	0

#	Article	IF	Citations
91	Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33?q34. Immunogenetics, 1990, 31, 198-201.	2.4	72